Gain Therapeutics, Inc. (NASDAQ:GANX) Director Eric I. Richman Purchases 17,000 Shares – Notice Important Internet

Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) Director Eric I. Richman purchased 17,000 shares of the company’s hit in a dealings on Monday, July 1st. The hit was acquired at an cipher toll of $1.22 per share, with a amount continuance of $20,740.00. Following the termination of the purchase, the administrator today direct owns 289,629 shares in the company, valued at $353,347.38. The acquisition was unconcealed in a writing filed with the SEC, which is acquirable finished the SEC website.

Gain Therapeutics Stock Performance

Gain Therapeutics stock unsealed at $1.12 on Tuesday. The consort has a hurried ratio of 2.77, a underway ratio of 2.77 and a debt-to-equity ratio of 0.05. Gain Therapeutics, Inc. has a dozen period baritone of $1.11 and a dozen period broad of $5.33. The company’s 50-day agitated cipher toll is $2.28 and its 200-day agitated cipher toll is $3.28. The consort has a mart container of $20.22 million, a PE ratio of -0.75 and a beta of 0.35.

Gain Therapeutics (NASDAQ:GANX – Get Free Report) terminal issued its quarterly earnings accumulation on Tuesday, May 14th. The consort reportable ($0.22) earnings per deal for the quarter, superior the consensus judge of ($0.30) by $0.08. On average, equities investigate analysts prognosticate that Gain Therapeutics, Inc. module place -1.11 EPS for the underway business year.

Analyst Ratings Changes

Several investigate firms hit fresh commented on GANX. Oppenheimer reissued an “outperform” judgement and issued a $9.00 direct toll on shares of Gain Therapeutics in a inform on Tuesday, Apr 23rd. Chardan Capital reissued a “buy” judgement and ordered a $6.00 toll neutral on shares of Gain Therapeutics in a inform on Wednesday, March 27th. Finally, HC Wainwright restated a “buy” judgement and ordered a $9.00 toll neutral on shares of Gain Therapeutics in a investigate inform on Tuesday, May 28th.

Read Our Latest Analysis on GANX

About Gain Therapeutics

(Get Free Report)

Gain Therapeutics, Inc, a engineering company, develops new diminutive mote therapeutics to impact diseases crossways different therapeutic areas. Its take brainstorm papers navigator discovers new allosteric protection sites in a disease; identifies copyrighted diminutive molecules that bond these sites to correct accelerator function; and treats the inexplicit drive of the disease.

Read More

Receive News & Ratings for Gain Therapeutics Daily – Enter your telecommunicate come beneath to obtain a apothegmatic regular unofficial of the stylish programme and analysts’ ratings for Gain Therapeutics and attendant companies with MarketBeat.com’s FREE regular telecommunicate newsletter.